BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: As per Fact.MR, the global cancer immunotherapy market is projected to total US$ 119.4 Bn by 2021.

SAGA Diagnostics AB, a leading cancer liquid biopsy and genomic testing company, has announced the appointment of Peter Collins as Chief Executive Officer.

The antisense oligonucleotides market is expected to gain extensive growth across the assessment period of 2020-2030.

The Xlife-project company inflamed pharma GmbH has concluded an exclusive license agreement with the Austrian Vitesse Trading GmbH for the sale of its active ingredient ProcCluster.

Inhalon Biopharma, Inc. today announced that the first patient has been dosed in a Phase 1 safety and tolerability study of IN-006 in healthy volunteers.

Blade Therapeutics, Inc. today announced peer-reviewed publication of preclinical study data supporting the neuroprotective effects of inhibiting dimeric calpains in spinocerebellar ataxia type-3 (SCA3).

- In Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial, upadacitinib (RINVOQ®) met the primary endpoint of ASAS40 at week 14 versus placebo (45 percent compared to 23 percent)[1]

Ovid Therapeutics Inc. today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the company will be featuring its SRT-100 Vision™ system live at the 2021 Fall Clinical Conference being held in Las Vegas, Nev. from October 21 to 24.

ALR Technologies today announces that the Company has released a new investor presentation that can be viewed at www.alrt.com/investors .